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INTRODUCTION
Control of inflammation and pain is important in veterinary medicine and several classes of drugs are used for this purpose. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used agents and are indicated for a variety of painful musculoskeletal conditions including osteoarthritis and after surgery (Golden & Abramson, 1999) . The class of NSAIDs which are selective inhibitors of the cyclooxygenase (COX)-2 isoenzyme were designed with the objective of having superior safety profiles, especially to the gastrointestinal tract, compared to nonselective COX inhibitors (Flower, 2003) . Robenacoxib is a selective COX-2 inhibitor with demonstrated efficacy in inhibiting fever, inflammation and pain, and a good safety profile for the gastrointestinal tract and kidney (King et al., , 2011 Schmid et al., 2010) .
Sodium urate crystal-induced stifle joint inflammation and pain is a well-established model for evaluating the anti-inflammatory and analgesic activities of new therapeutic agents in dogs Phelps et al., 1966; Schumacher et al., 1974; Rumph et al., 1993; Millis et al., 2002; Borer et al., 2003) . Schmid et al. (2010) previously used this model in dogs to establish the dose-related effects of robenacoxib when administered by subcutaneous injection.
The objective of this study was to determine the efficacy and dose-response relationship of orally administered robenacoxib in the urate model of stifle joint inflammation.
MATERIALS AND METHODS
The study was conducted in compliance with Good Clinical Practice (VICH GL 9, July 2001) with a protocol approved by the Elanco Animal Health Research Centre in St-Aubin, Switzerland, and in compliance with the Swiss law for animal protection. The study design followed the CVMP guideline on the conduct of efficacy studies for NSAIDs (EMA/CVMP/EWP/ 1061/2001), which recommends a dose titration study testing a minimum of three doses with the anticipated recommended dose (1-2 mg/kg) as the middle dose. The manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments (Kilkenny et al., 2010) .
Animals
Twelve healthy beagle dogs (six males, six females) were included in the study and were selected based on physical examination, haematology and blood chemistry results on day 0. Dogs were housed in groups of two or three in pens and acclimatized for 4 weeks before the start of the study. They were fed with commercially available dog food once daily and were provided with water ad libitum.
Inclusion and exclusion criteria
Healthy beagle dogs with no known orthopaedic disorder were eligible for inclusion. Dogs with known pre-existing stifle arthritis or diseases likely to cause marked differences in weight bearing between limbs were excluded. Postadministration exclusion criteria included data from the dogs which were not lame 3 h after administration of the urate crystals, and dogs which developed lameness due to reasons other than administration of the urate.
Study design
The study was a dose titration of single oral administration of robenacoxib (five dosages) compared with negative (placebo) and positive (meloxicam) controls. The study employed a seven phase partial Latin square design with randomized sequence, so that every dog received each treatment once. Female and male dogs were randomized separately.
Food was withheld for 15 h prior to initiation of each phase of the study, and the dogs were fed again 12 h after administration of the test items. The dogs had been trained previously to use the force plate, and gait prevalues were recorded at À3.5 h. The dogs were sedated to allow injection of urate crystals into a stifle joint. At 0 h, the dogs were checked visually. If the dogs were lame (i.e. nonweight bearing on their injected leg), they were administered one of the test items and underwent additional force plate examinations and subjective clinical orthopaedic scoring. Venous blood samples were taken for determination of blood robenacoxib concentration plus COX-1 and COX-2 activities. Dogs that were not lame 3 h after injection of urate crystals were excluded from the respective part of the study (this occurred twice in two dogs and once in one dog, i.e. a total of five times with 84 injections).
The procedures were performed seven times with a minimum 14-day washout period. Alternate stifle joints were used to create a minimum 4-week recovery time for each joint.
Urate synovitis model
Lameness was induced using the urate synovitis model Phelps et al., 1966) . Briefly, the day prior to administration, 15 mg of dry sodium urate crystals were prepared in 2 mL physiological saline (NaCl 0.9%) in small glass vials, which were then sterilized in an autoclave.
Approximately 3.5 h before administration of the test treatments, each dog was sedated with medetomidine (20-80 lg/kg, intravenous) (Domitor â , Orion Corporation, Espoo, Finland) to facilitate the accurate and humane intra-articular injection of 15 mg sodium urate crystals into a stifle joint. The intrasynovial injections were administered lateral to the patellar ligament using a 20-G needle and a sterile technique. Immediately after intra-articular injection of the urate, the action of medetomidine was reversed by administering an equal volume of atipamezole (Antisedan â , Orion Corporation, Espoo, Finland, 20-80 lg/kg, intravenous). Although all dogs were treated, the use of sedation introduces the possibility of a sedation x test item interaction. The lameness induced in this model was no longer present at 24 h.
Treatments
The following test items were administered orally: (i) robenacoxib in the form of tablets containing 2.5 mg or 10 mg of active ingredient (Elanco Animal Health, Basel, Switzerland); (ii) meloxicam in the form of an oral suspension with 1.5 mg active ingredient per mL (Boehringer Ingelheim, Ingelheim, Germany); and (iii) placebo in the form of placebo tablets with the same size and composition as the 10 mg robenacoxib tablets except that the active ingredient was replaced by lactose (Elanco Animal Health, Basel, Switzerland). Robenacoxib was administered at dosages of 0 (placebo), 0.5, 1, 2, 4 and 8 mg/kg. Meloxicam was administered at a dosage of 0.1 mg/kg, which is the maintenance dose registered in the EU for long-term administration to dogs. Doses were calculated based on individual dog body weights measured at day 1.
Efficacy assessment -Force plate kinetic gate analysis
The primary endpoint of the study was the weight bearing on the force plate assessed pre-injection (À3.5 h) of urate, postinjection of urate (0 h, immediately before administration of the test items) and then at +0.5, 1, 2, 3, 4, 5 and 6 h after administration of the test items. The main primary endpoint was the maximal vertical force of the force plate (z peak force (ZPF), measured in Newton/kg body weight (N/kg)) for the urate-injected limb compared to the contralateral limb. Additional force plate variables were the area under curve (AUC) of the vertical force of each step on the force plate (z impulse (ZI), measured in N/kg) and the time during which a leg applied the ZPF on the force plate (z peak time (ZPT), in ms). A biomechanical platform (Model OR6-6-100, Advanced Mechanical Technologies Inc, Watertown, MA, USA), embedded in a 10 m length pathway, was used. Each dog was trotted on a leash across the plate to maintain a constant speed. To have a valid passage, the dog had to strike the force plate with either the left or right front leg followed by the ipsilateral rear leg. Six valid hits completed a measurement. The ZPF was processed according to the relationship: ZPF injected leg ZPF injected leg prevalue ZPF injected leg ZPF injected leg prevalue þ ZPF opposite rear leg ZPF opposite rear leg prevalue The same procedure was used for ZI and ZPT. This formula takes into account the pre-and postinjection weight bearing of both the injected and contralateral noninjected limbs. This formula was found to be reliable in preliminary studies in which different formulae were evaluated. Median values were calculated over all measurements for each time point and leg.
Values of maximum inhibition (Emax) and times of onset of action and maximum inhibition (TEmax) were determined.
Efficacy assessments -Clinical orthopaedic examinations
Secondary efficacy endpoints were subjective scores derived from clinical orthopaedic examinations of both the injected and noninjected limbs. Numerical rating scales were used and were adapted from those used by Renberg et al. (2000) . Examinations were conducted on day 0 and then at 0, 3 and 6 h posturate on day 1. Assessments were conducted independently by two veterinarians who were blinded to the treatment groups.
Weight bearing was assessed on a five-point scale: 0 = normal weight bearing at rest and during gait; 1 = normal weight bearing at rest, partial weight bearing during gait; 2 = partial weight bearing both at rest and during gait; 3 = partial weight bearing at rest, no weight bearing during gait; and 4 = no weight bearing at rest or during gait. Pain on palpation was assessed on a five-point scale: 0 = normal (no signs of pain); 1 = signs of mild pain (e.g. turns head); 2 = signs of moderate pain (e.g. pulls leg away); 3 = signs of severe pain (e.g. vocalizes or shows aggression); and 4 = will not allow limb palpation. Swelling was assessed on a four-point scale: 0 = normal (no swelling); 1 = slight swelling; 2 = moderate swelling; and 3 = marked swelling. Assessments of the two investigators were in good agreement (90% matched exactly and 99% differed by not more than one point). The median of the two scores was therefore taken for each dog at each time point.
Ex vivo COX-1 and COX-2 assays
Ex vivo measurements of COX-1 and COX-2 activities were made using whole-blood assays on blood samples collected before (0 h) and after (+1, 2 and 6 h) dosing with the test items.
COX-1 activity was determined in blood samples collected into plastic tubes without anticoagulant (S-Monovette 2.7 mL, Sarstedt AG, Sevelen, Switzerland). Aliquots of 500 lL of blood were pipetted into microtubes, which were mixed and then incubated at 37°C for 1 h, followed by centrifugation at 16 000 g at 4°C for 10 min. The supernatant serum was collected and stored at À18°C or below prior to determination of thromboxane B 2 (TxB 2 ) concentration using a commercial kit (RPN220-TxB 2 , Biotrak EIA, GE Healthcare Europe GmbH, Otelfingen, Switzerland).
For the COX-2 assay, blood was collected into plastic tubes containing citrate as anticoagulant (S-Monovette 2.7 mL NC, Sarstedt AG, Sevelen, Switzerland). The following procedures were performed using sterile techniques under laminar flow. Aliquots of 1000 lL blood were pipetted into sterile microtubes followed by addition of 5 lL lipopolysaccharide (LPS, L-2630 Escherichia coli Serotype 0111:B4, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). After vortexing, tubes were incubated for 24 h at 37°C and then centrifuged at 16 000 g at 4°C for 10 min. The supernatant plasma was collected and stored at À18°C or below prior to assay of prostaglandin E 2 (PGE 2 ) using a commercial kit (RPN222-PGE2, Biotrak EIA, GE Healthcare Europe GmbH, Otelfingen, Switzerland).
Pharmacokinetics of robenacoxib
Blood samples taken before (0 h) and after (+0.5, 1, 2, 4 and 6 h) dosing with the test items were analysed for robenacoxib concentration using the high-performance liquid chromatography with the ultraviolet detection (HPLC-UV) and liquid chromatography-mass spectrometry (LC-MS) methods described and validated by Jung et al. (2009) . Quality control samples were included in each run.
For the HPLC-UV and LC-MS methods, interassay inaccuracies ranged from 0.4 to 5.4 and from 1.8 to À4.1, respectively. Corresponding values for precision were, respectively, 3.2-7.1% and 2.8-9.6%. At all concentrations, inaccuracy and precision values were within guidelines (FDA, 2001 ). Intraassay inaccuracy and precision values were similar to those for interassay. The lower limit of quantification, considering accuracy and precision data, was set to 2.0 ng/mL. Pharmacokinetic variables were determined from blood robenacoxib concentrations using a software (Data Evaluation in BioAnalytics, release 4.1 XP, Copyright Dr C.N. Thumm-Kraus, Software & Consulting, 1999, Basel, Switzerland) as follows: AUC[0-6 h], AUC from 0 to 6 h; AUC[0-infinity], AUC from 0 to infinity; C max , maximum blood concentration; T max , time of maximum blood concentration; t ½ , terminal half-life. AUC[0-6 h] was calculated using the trapezoidal rule. AUC [0-infinity] was calculated from the sum of AUC[0-t] plus AUC[t-infinity], the latter determined by extrapolation from the last time point (t) using k, where k is the rate constant for the terminal decline phase, determined by linear regression of the plot of log concentration vs. time; t ½ was calculated from t ½ = ln 2/k.
Statistical analysis
All calculations were performed using the software SAS â (SAS Online Version 8, SAS Institute Inc, Cary, NC, USA). Statistical significance was defined in all cases with two-tailed P values less than 0.05, with no correction for multiple tests in order not to inflate the type II error.
For the force plate variables (ZPF, ZI and ZPT), means over the time periods 0-3, 3-6 and 0-6 h, divided by the prevalue, were analysed using analysis of variance (ANOVA) methods as the data fulfilled normal distribution assumptions without any transformations. The following effects were included in the model: animal, birth date, body weight, sex, treatment group, administration number (per animal), batch of urate, joint (left or right) and operator. Variables which did not have a significant (P > 0.1) effect were dropped from the model in a stepwise manner, with the exception of animal which was assumed to always differ. The variables animal, batch of urate and treatment group were significant for all three endpoints for one or more time periods. However, animal and batch had to be removed from the model to permit final estimation of the effect of treatment. Post hoc group comparisons were made using the Dunnett-Hsu test.
For estimation of the dose which produced 50% of the maximal response (ED 50 ), the standard sigmoidal curve model was used. Onset of action, E max and TE max were compared between groups using the Mann-Whitney U-test.
The secondary variables, subjective orthopaedic scores (weight bearing, pain on palpation and swelling) and concentrations of PGE 2 and TxB 2 , were not normally distributed and therefore were analysed using nonparametric methods. The Mann-Whitney U-or Kruskal-Wallis tests were used for unpaired and the Wilcoxon test for paired sample comparisons. For the orthopaedic scores, the following effects were assessed: administration number (three categories), batch of urate (two categories), birth date (two categories), body weight (13 kg or less, >13 kg), joint (left or right), operator (two people) and gender. For each covariate, a stratified version of the MannWhitney U-test (for two categories) or the Kruskal-Wallis test (for more than two categories) was used to compare the categories of the covariate. Of the seven tested effects, three were relevant: administration number, batch of urate and birth date.
The pharmacokinetic variables were analysed using ANOVA as the data fulfilled assumptions for a normal distribution after log transformation.
RESULTS
At the start of the study, the dogs were aged 15-114 months and weighed 9.4-14.1 kg.
Force plate endpoints
Similar results were obtained with the three force plate variables (ZPF, ZI and ZPT). Spontaneous recovery of weight bearing in the negative control group commenced at median 5 h (range 3-6 h) after administration of the placebo and increased progressively but variably (Fig. 1) . Full recovery had occurred by 24 h in all dogs. The mean weight bearing in the meloxicam and robenacoxib (all doses) groups was higher at all time points 1-6 h compared with the placebo.
The percentage increase in force plate variables (ZPF, ZI and ZPT) in the meloxicam and robenacoxib treatment groups compared to the placebo is shown in Table 1 with P values in Table 2 . The increase in all three force plate variables was significantly higher in the meloxicam and all robenacoxib groups compared with placebo for one or more of the time periods (Table 2 ). The percentage increase for ZPF ranged from 20 to 43%, 19 to 72% and 20 to 58% at 0-3, 3-6 and 0-6 h, respectively, for all doses of robenacoxib and was 15, 44 and 30% in the meloxicam group (Table 1) .
The increase in force plate variables was significantly higher in the 2 and 8 mg/kg robenacoxib groups at earlier time intervals (0-6 h and/or 0-3 h) compared with the meloxicam group. In comparison with meloxicam for ZPF, P = 0.0046 at 2 mg/kg and P = 0.0038 at 8 mg/kg during 0-3 h, with P = 0.021 at 8 mg/kg during 0-6 h.
There was a dose-dependent increase in the effect of robenacoxib for all three force plate variables (ZPF, ZI and ZPT) over the 0.5-2 mg/kg dose range, beyond which (4-8 mg/kg) the response was maintained and no additional benefit was observed. Further analysis of the dose-response relation was carried out to derive the ED 50 and Hill plot (b) values. Both mean values for all dogs and curve fitting in individual dog approaches were used and produced similar results. Mean values for all dogs are shown in Table 3 . The ED 50 for the 0-6 h time period was estimated as 0.6-0.8 mg/kg.
The placebo-treated dogs recovered spontaneously, leading to times for onset of action (5 h) and to maximal effect (6 h) using ZPF (Table 4) . Similar results were observed for ZI and ZPT (data not shown). The median time to onset of action for robenacoxib was faster (2-2.5 h) than with the placebo (5 h) or meloxicam (3 h). Differences were statistically significant (P < 0.01) for all five doses of robenacoxib compared with placebo, and for the 2 mg/kg robenacoxib dose compared to meloxicam (P = 0.0096). Significantly (P < 0.05) higher E max values for robenacoxib were observed compared to placebo for all five doses and compared to meloxicam for the higher doses (2-8 mg/kg). The median time to reach TE max was faster with robenacoxib (3-5 h) compared to meloxicam (6 h), and differences reached statistical significance for the 0.5, 2 and 8 mg/kg groups and for all groups combined. The TE max was significantly faster with all five doses of robenacoxib compared to the placebo.
Clinical orthopaedic examinations
Results of the subjective clinical orthopaedic measurements, the extent of weight bearing, pain on palpation and swelling The parameters y 0 and y ∞ are, respectively, the estimates for the responses with 0 and infinite dose. Mean values from all dogs were used for the curve fitting. n.c., not calculated.
of the injected stifle joint, are shown in Fig. 2a-c, respectively . Each group was compared statistically to the meloxicam and placebo groups separately. Results were similar when groups were treated as independent (Mann-Whitney U-test) or paired values from the same animal were compared (Wilcoxon paired sample test). Three covariates, administration number, batch of urate and body weight, had a significant effect for at least one variable at one time point. Analysis with stratification for these covariates using the Mann-Whitney U-test led to similar conclusions as the unstratified analyses. Therefore, only results of the unstratified analyses using the Wilcoxon test are reported below. There were no significant differences between groups at baseline (0 h). Mean values were lower in the meloxicam and all robenacoxib groups compared to the placebo for all three endpoints at both the 3-h and 6-h time points (Fig. 2a-c) . For extent of weight bearing, differences were significant from placebo (P < 0.05) for the 1, 2, 4 and 8 mg/kg robenacoxib groups at 3 h, and for the meloxicam and 2 and 4 mg/kg robenacoxib groups at 6 h. For pain at palpation, differences were significant from placebo for the 2 mg/kg (3 and 6 h) and 4 mg/kg (3 h) robenacoxib groups. For joint swelling, differences were significant from placebo (P < 0.05) for the 0.5, 4 and 8 mg/kg robenacoxib groups at 3 h, and for the meloxicam and 0.5, 2, 4 and 8 mg/kg robenacoxib groups at 6 h.
Inhibition of COX-1 and COX-2
Figures 3 and 4 show TxB 2 and PGE 2 concentrations as markers of COX-1 and COX-2 activity, respectively, measured predosing (0 h) and 1, 2 and 6 h postdosing. The only test item group with a significant inhibition of TxB 2 (COX-1) was the highest (8 mg/kg) dose of robenacoxib at the 1 h time point (P = 0.043). In contrast, all five doses of robenacoxib produced significant (P < 0.05) and dose-related inhibition of PGE 2 at both the 1-and 2-h post-treatment time points. The mean maximal inhibition vs. baseline was as follows: placebo, À4.8%; 0.5 mg/kg, 50.0%; 1 mg/kg, 65.1%; 2 mg/kg, 79.1%; 4 mg/kg, 84.5%; and 8 mg/kg, 84.2%. Meloxicam had no significant effect on PGE 2 or TxB 2 at any time points.
Pharmacokinetics of robenacoxib
Blood concentrations of robenacoxib were below the lower limit of quantification of the assay (<1 ng/mL) at all time points in the placebo and meloxicam groups, as well as 3.5 h before dosing in the robenacoxib groups. Blood concentrations of robenacoxib were used to derive pharmacokinetic variables (Fig. 5 , Table 5 ). There was no significant effect of sex on any variable. The oral administration of robenacoxib in tablets to the dogs without feed led to rapid absorption (median T max 1.25 h) and elimination (harmonic mean terminal t 1/2 0.8 h). The exposure of robenacoxib was found to be linear as AUC values increased in proportion to increased dose, and T max and t 1/2 values did not differ between doses. . COX-1 activity in blood samples from dogs. COX-1 activity was assessed from serum TxB 2 concentrations generated ex vivo by clotting of whole blood. Test items were administered orally at time 0, 3 h after intra-articular injection of urate crystals. Symbols are mean and vertical lines are SD (n = 12). To add clarity, symbols are distributed around the true time points (pretreatment (0), 1, 2 and 6 h). Fig. 4 . COX-2 activity in blood samples from dogs. COX-2 activity was assessed from plasma PGE 2 concentrations generated ex vivo by incubation of blood samples with LPS. Test items were administered orally at time 0, 3 h after intra-articular injection of urate crystals. Symbols are mean and vertical lines are SD (n = 12). To add clarity, symbols are distributed around the true time points (pretreatment (0), 1, 2 and 6 h).
antihyperalgesic) and anti-inflammatory effects with significant improvement in extent of weight bearing, pain on palpation and joint swelling compared to the placebo group. Effects were positively correlated with dose of robenacoxib from 0.5 to 2 mg/kg with no further increase in effect from 2 to 8 mg/kg. Robenacoxib had a relatively fast onset of action (2-2.5 h, vs. 3 h for meloxicam) which correlates with its relatively fast absorption, the T max being 0.5 h after oral tablet administration (Jung et al., 2009 ). Robenacoxib had equivalent or greater efficacy than 0.1 mg/kg meloxicam at doses of 1 mg/kg and higher. Similar effects of robenacoxib after subcutaneous injection in the urate model in dogs were described previously (Schmid et al., 2010) . The design of the present study, with repeated treatment using a seven phase partial Latin square, required an acute model, and hence the urate crystal model was suitable. The short duration of the inflammatory process induced by the urate crystals ensured that a washout period of 2 weeks between phases and 4 weeks for each joint was sufficient. The urate crystals resulted in loss of weight bearing which started to resolve spontaneously in the placebo group after median 5 h (range 3-6 h) and the dogs were clinically normal within 24 h, in accordance with previous reports Phelps et al., 1966; Rumph et al., 1993; Cross et al., 1997; Hazewinkel et al., 2003; Schmid et al., 2010) . The urate model is considered to be very acceptable ethically (Hazewinkel et al., 2008) as the pain and inflammation is transient and leaves no permanent effects. In addition, the urate model is a well-established system for evaluating NSAIDs (Van Arman et al., 1970; Okuda et al., 1984) and has been used in dogs to test both selective and nonselective COX inhibitors (Cross et al., 1997; Toutain et al., 2001a; Millis et al., 2002; Borer et al., 2003; Hazewinkel et al., 2008) .
The primary objective of the study was to establish the efficacy and dose-response relationship for the analgesic and anti-inflammatory effects of robenacoxib, as measured by improvement in weight bearing, pain on palpation and swelling. The primary endpoint was the weight bearing assessed objectively by the force plate, with the ZPF as the main endpoint (Borer et al., 2003) . The primary objective of the study was achieved as robenacoxib showed dose-related efficacy in improving weight bearing, as determined by all three force plate variables (ZPF, ZI and ZPT) and the subjective assessment endpoints. Efficacy increased over the dose range 0.5-2 mg/kg, with a plateau response from 2 to 8 mg/kg, and the ED 50 was estimated at 0.6-0.8 mg/kg. In a previous study, in which robenacoxib was administered subcutaneously, the response increased over the dose range of 0.25-4 mg/kg and the ED 50 was estimated as 0.90-1.23 mg/kg (Schmid et al., 2010) . The main reason for the higher ED 50 estimate with the injection is the fact that the efficacy of the injection was assessed over a longer time (up to 12 h) compared to only 6 h with the tablets in this study (Schmid et al., 2010) . Toutain et al. (2001b) concluded previously that the ED 50 dose for NSAIDs in the urate synovitis model may be appropriate for treatment of chronic conditions. Based on results of this study, robenacoxib tablets at a minimum dose of 1 mg/kg (range 1-2 mg/kg) were tested subsequently in a field study of osteoarthritis in dogs and found to be efficacious and well tolerated (Reymond et al., 2012) . As a complement to the force plate measurements, subjective orthopaedic evaluations of weight bearing, pain on palpation and swelling were conducted as in previous studies (Rosenthale et al., 1966; Holtsinger et al., 1992; Budsberg et al., 1996 Budsberg et al., , 1999 Borer et al., 2003) . In the current study, robenacoxib exhibited dose-related efficacy which was statistically significant for all three endpoints, thus supporting the results from the force plate which assessed weight bearing.
Ex vivo analyses of concentrations of PGE 2 , as an index of COX-2 activity, and TxB 2 , as an index of COX-1 activity, confirmed the COX-2 selective activity of robenacoxib, as reported previously both in vitro and in vivo in dogs Schmid et al., 2010) . The results show that oral administration of robenacoxib over the dose range 0.5-4 mg/kg led to significant inhibition of COX-2 with no detectable effect on COX-1 in the dogs, that is it was 'COX-1 sparing'. At the highest dose of 8 mg/kg, robenacoxib produced transient inhibition of COX-1. However, safety data in dogs have demonstrated that transient inhibition of both COX-1 and COX-2 with robenacoxib each day in dogs did not lead to detectable toxicity even at high doses (up to 40 mg/kg daily for 28 days, King et al., 2011) . In this study, single doses of robenacoxib were tolerated well and induced no significant changes in clinical chemistry or haematology variables (data not shown).
Meloxicam is reported to have low selectivity for COX-2 in dogs, for example the ratio of IC 50 values for COX-1 vs. COX-2 was 7.3 in King et al. (2010) . In this study, oral 0.1 mg/kg meloxicam had no detectable effect on either COX-1 or COX-2 and no significant effect on pain on palpation, but had significant efficacy vs. placebo on weight bearing and joint swelling. The dose of meloxicam tested was 0.1 mg/kg, administered as a single application. The registered dose regimen of oral meloxicam for dogs in the EU is a single loading dose of 0.2 mg/kg on day 1 followed by a maintenance dose of 0.1 mg/kg on subsequent days. Greater effects (on pain, inflammation, COX-1 and COX-2) might therefore have been obtained with the 0.2 mg/kg dose of meloxicam.
In conclusion, in this study a tablet formulation of robenacoxib produced significant dose-dependent analgesic and anti-inflammatory effects in dogs with acute synovitis joint inflammation. Efficacy was dose-related over the range 0.5-2 mg/kg and reached a plateau at 2-8 mg/kg. The ED 50 was 0.6-0.8 mg/kg. The efficacy of robenacoxib at doses of 1 mg/kg and above was equivalent or greater than that produced by 0.1 mg/kg meloxicam, and robenacoxib had a faster onset of action. Over the dose range 0.5-4 mg/kg, robenacoxib significantly inhibited COX-2 and had no effect on COX-1.
